Monocytic aleukemic leukemia cutis. 1999

L Török, and S Lueff, and G Garay, and M Tápai
Department of Dermatology, County Hospital of Bács-Kiskun County, Kecskemét, Hungary.

The authors present a case of monocytic aleukemic leukemia cutis in which skin symptoms were the sole manifestation of the leukemia during the first year and a half of the disease. Diagnostic difficulties, the importance of immunohistochemical markers, and the prognosis and therapy of aleukemic leukemia cutis are discussed.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D001707 Biopsy, Needle Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed. Aspiration Biopsy,Puncture Biopsy,Aspiration Biopsies,Biopsies, Aspiration,Biopsies, Needle,Biopsies, Puncture,Biopsy, Aspiration,Biopsy, Puncture,Needle Biopsies,Needle Biopsy,Puncture Biopsies
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D015479 Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin. Leukemia, Myeloid, Acute, M4,Leukemia, Myeloid, Naegeli-Type,Myeloid Leukemia, Acute, M4,Myeloid Leukemia, Naegeli-Type,Myelomonocytic Leukemia, Acute,Acute Myelomonocytic Leukemia,Acute Myelomonocytic Leukemias,Leukemia, Acute Myelomonocytic,Leukemia, Naegeli-Type Myeloid,Leukemias, Acute Myelomonocytic,Myeloid Leukemia, Naegeli Type,Myelomonocytic Leukemias, Acute,Naegeli-Type Myeloid Leukemia
D017254 Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site. Infiltration, Leukemic,Infiltrations, Leukemic,Leukemic Infiltrations

Related Publications

L Török, and S Lueff, and G Garay, and M Tápai
November 1988, [Rinsho ketsueki] The Japanese journal of clinical hematology,
L Török, and S Lueff, and G Garay, and M Tápai
February 1996, Mayo Clinic proceedings,
L Török, and S Lueff, and G Garay, and M Tápai
April 2002, Cutis,
L Török, and S Lueff, and G Garay, and M Tápai
May 1997, Journal of the American Academy of Dermatology,
L Török, and S Lueff, and G Garay, and M Tápai
September 2008, Puerto Rico health sciences journal,
L Török, and S Lueff, and G Garay, and M Tápai
March 1976, Archives of dermatology,
L Török, and S Lueff, and G Garay, and M Tápai
February 1990, Journal of the American Academy of Dermatology,
L Török, and S Lueff, and G Garay, and M Tápai
July 1986, Archives of dermatology,
L Török, and S Lueff, and G Garay, and M Tápai
February 2019, Cleveland Clinic journal of medicine,
L Török, and S Lueff, and G Garay, and M Tápai
January 2007, Indian journal of dermatology, venereology and leprology,
Copied contents to your clipboard!